A young man has been diagnosed with acute stage 3 leukemia and urgently needs help to survive. He has appealed to the general ...
Tuspetinib based TUS+VEN+AZA triplet therapy is being advanced in the TUSCANY Phase 1/2 trial with the goal of creating an improved frontline therapy for newly diagnosed AML patients that is active ...
A new study evaluating the quadratic phenotypic optimization platform shows it can accurately predict personalized drug ...
Interesting trends were observed in the subgroup analyses of the phase 3 uproleselan study in relapsed or refractory acute ...
Researchers sought to determine if HRQoL measures differ with gilteritinib compared with placebo in patients with AML.
Medically reviewed by Doru Paul, MD Leukemia is a cancer of the blood-forming tissues that often develops in the bone marrow.
David Sallman, MD, Moffitt Cancer Center, discussed the trial's impact and the future role of MRD monitoring in treatment ...
Two posters presented at the 2024 American Society of Hematology meeting reported real-world outcomes data for patients ...
Venetoclax is under clinical development by AbbVie and currently in Phase II for Relapsed Acute Myeloid Leukemia.
In a significant advancement for cancer research, a team of scientists from Max Planck Institute for Biology Tübingen, ...